Clinical trials: Leiomyosarcomas
Liposarcoma, Leiomyosarcoma
A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer
The purpose of this study is to test the safety and effectiveness of an investigational chemotherapy agent in patients with types of advanced cancer referred to as liposarcoma or leiomyosarcoma.
- Trial name
- NCT00060944
- Testing
- Yondelis, Dexamethasone
- Where
- 39 sites in United States, Australia and 6 more
- Volunteers
- 271 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Leiomyosarcoma, Liposarcoma
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
This study will evaluate the safety and efficacy of MASCT-I combined with Doxorubicin and Ifosfamide for first-line treatment in patients with advanced soft tissue sarcoma.
- Conditions
- Leiomyosarcoma, Liposarcoma, Synovial Sarcoma, Angiosarcoma
- Trial name
- NCT06277154
- Testing
- MASCT-I, Doxorubicin, Ifosfamide
- Where
- China
- Volunteers
- 148 people
- Sponsor
- HRYZ Biotech Co.
Tumor
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
This is a study to assess the combination of PXD101 and 5-Fluorouracil (5-FU)in patients with advanced solid tumors. The primary goal of the study is to understand the safety, anti-tumor activity, and how the study drug behaves…
- Trial name
- NCT00413322
- Testing
- belinostat, 5-Fluorouracil (5-FU)
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Valerio Therapeutics
Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders
Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies
The primary objective of this protocol is to provide expanded access to tabelecleucel to participants with Epstein-Barr virus-associated diseases and malignancies for whom there are no other appropriate therapeutic options, and…
- Conditions
- Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders, EBV+ Associated Lymphoma, EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)
- Trial name
- NCT02822495
- Testing
- tabelecleucel
- Sponsor
- Atara Biotherapeutics
Solid Tumor, Triple-negative Breast Cancer
A Study of LY3435151 in Participants With Solid Tumors
The reason for this study is to see if the study drug LY3435151 is safe in participants with advanced solid tumors.
- Conditions
- Solid Tumor, Triple-negative Breast Cancer, Gastric Adenocarcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT04099277
- Testing
- LY3435151, Pembrolizumab
- Where
- 2 sites in United States, Japan
- Volunteers
- 2 people
- Sponsor
- Eli Lilly and Company
Sarcoma, Soft Tissue
Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma
The purpose of this study is to evaluate the activity and tolerability of pazopanib in subjects with advanced and/or metastatic soft tissue sarcoma who have relapsed following standard therapies or for whom no standard therapy…
- Trial name
- NCT00297258
- Testing
- pazopanib
- Where
- 16 sites in Belgium, France and 3 more
- Volunteers
- 148 people
- Sponsor
- GlaxoSmithKline
Life Threatening Diseases
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Exploratory study to examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate -sensitive tyrosine kinases, and to identify the contribution of…
- Trial name
- NCT00154388
- Testing
- Imatinib mesylate
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Soft Tissue Sarcoma
Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
To compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.
- Trial name
- NCT05712694
- Testing
- ADI PEG20
- Where
- 30 sites in United States, Canada and 1 more
- Volunteers
- 218 people
- Sponsor
- Polaris Group
Leiomyoma, Uterine, Leiomyosarcoma Uterus
Accuracy of the Preoperative Molecular Diagnosis of Uterine Tumors by Liquid Biopsy
The development of precise and non-invasive diagnostic methods is a priority in areas such as gynaecology and oncology, and above all in improving the health of those patients with a surgical indication for hysterectomy…
- Trial name
- MYOSARCII (NCT04935333)
- Testing
- Collection of Leiomyoma samples, Collection of Leiomyosarcoma samples, Collection of control samples
- Where
- 21 sites in Spain
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Igenomix
Sarcoma
Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy such as soblidotin use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00064220
- Testing
- soblidotin
- Where
- 6 sites in United States, Puerto Rico
- Sponsor
- Daiichi Sankyo
Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
BBI-355 is an oral, potent, selective checkpoint kinase 1 (or CHK1) small molecule inhibitor in development as an ecDNA (extrachromosomal DNA) directed therapy (ecDTx).
- Conditions
- Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma, Anogenital Cancer
- Trial name
- POTENTIATE (NCT05827614)
- Testing
- BBI-355, Erlotinib, Futibatinib
- Where
- 16 sites in United States
- Volunteers
- 85 people
- Sponsor
- Boundless Bio, Inc.
Leiomyosarcoma
Exploring Clinical Trial Experiences of People With Leiomyosarcoma
Clinical study participation has historically been heavily biased toward specific demographics. Several people will be invited to enroll in this study so that it may collect a variety of data about leiomyosarcoma clinical trial…
- Trial name
- NCT05548179
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Leiomyosarcoma, Liposarcoma
Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
The purpose of this study is to assess the efficacy of ridaforolimus when administered once daily for 5 consecutive days (QDx5) every two weeks in participants with advanced sarcoma.
- Conditions
- Leiomyosarcoma, Liposarcoma, Osteosarcoma, Sarcoma, Soft Tissue
- Trial name
- NCT00093080
- Testing
- ridaforolimus
- Volunteers
- 216 people
- Sponsor
- Merck Sharp & Dohme LLC
Leiomyosarcoma
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
The primary objective of this phase III trial is to evaluate whether the combination of lurbinectedin plus doxorubicin given as first line treatment for metastatic leiomyosarcoma (LMS) prolongs the progression-free survival (PFS)…
- Trial name
- SaLuDo (NCT06088290)
- Testing
- Lurbinectedin, Doxorubicin
- Where
- 97 sites in United States, Austria and 10 more
- Volunteers
- 469 people
- Sponsor
- PharmaMar
Osteosarcoma, Ewing Sarcoma Family Tumors
Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung
The purpose of this Phase 2 study is to investigate whether intravenous administration of REOLYSIN® therapeutic reovirus is safe and effective in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung.
- Conditions
- Osteosarcoma, Ewing Sarcoma Family Tumors, Malignant Fibrous Histiocytoma, Sarcoma, Synovial
- Trial name
- NCT00503295
- Testing
- REOLYSIN®
- Where
- 4 sites in United States
- Volunteers
- 53 people
- Sponsor
- Oncolytics Biotech
Alveolar Soft Part Sarcoma, Leiomyosarcoma
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
THIS STUDY IS CURRENTLY RECRUITING PATIENTS WITH ALVEOLAR SOFT PART SARCOMA ONLY AND IS NO LONGER RECRUITING PATIENTS WITH SYNOVIAL SARCOMA OR LEIOMYOSARCOMA.
- Conditions
- Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma, Soft-Tissue Sarcoma
- Trial name
- APROMISS (NCT03016819)
- Testing
- AL3818, Dacarbazine, Midazolam 2 mg for CYP3A4 phenotyping
- Where
- 24 sites in United States, China and 3 more
- Volunteers
- 325 people
- Sponsor
- Advenchen Laboratories, LLC
Cancer, Tumor, Solid
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR2805…
- Conditions
- Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer
- Trial name
- NCT05094804
- Testing
- OR2805, Cemiplimab, Docetaxel
- Where
- 3 sites in United States
- Volunteers
- 172 people
- Sponsor
- OncoResponse, Inc.
Advanced or Metastatic Liposarcoma or Leiomyosarcoma
A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma
The purpose of this study is to find the optimal dose of trabectedin for Chinese patients with locally advanced or metastatic L-sarcoma (liposarcoma or leiomyosarcoma) who were previously treated (in any order) with at least an…
- Trial name
- NCT01692678
- Testing
- Trabectedin, Dacarbazine
- Where
- 2 sites in China
- Volunteers
- 16 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Leiomyosarcoma
A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma
The purpose of this study is to learn about the safety and effects of the study medicine (called Ontorpacept or TTI-621) when given alone and when given in combination with doxorubicin for people with leiomyosarcoma.
- Trial name
- TTI-621-03 (NCT04996004)
- Testing
- Ontorpacept (TTI-621), Doxorubicin
- Where
- 23 sites in United States
- Volunteers
- 76 people
- Sponsor
- Pfizer
Solid Tumor
A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes
A Phase 2, open-label, single-arm trial to evaluate the response of rucaparib in participants with various solid tumors and with deleterious mutations in Homologous Recombination Repair (HRR) genes.
- Trial name
- LODESTAR (NCT04171700)
- Testing
- Rucaparib
- Where
- 19 sites in United States
- Volunteers
- 83 people
- Sponsor
- pharmaand GmbH